肺癌患者神经元自身抗体与认知障碍的关联
这项前瞻性横断面研究纳入德国柏林单中心167例肺癌患者,采用贝叶斯逻辑回归分析神经元自身抗体与认知障碍的关联。结果显示36.5%患者检出脑靶向自身抗体,97例完成神经心理测试者中67.0%存在认知障碍;SCLC患者中任何自身抗体阳性者认知障碍比值比为11.0(95%CrI 1.2-103.6)。
要点
- 肺癌患者中超过三分之一可检出神经元自身抗体。
- SCLC患者自身抗体阳性与认知障碍风险升高相关。
- NSCLC中IgA型抗NMDAR抗体与言语记忆缺陷相关。
核心结论
- 超过三分之一的肺癌患者存在神经元自身抗体,且与认知障碍相关。
- 这些自身抗体可能代表肺癌患者免疫介导认知障碍的可治疗机制。
研究设计与样本
- 前瞻性横断面研究,2015年6月至2016年4月在德国柏林单中心纳入167例肺癌患者(SCLC和NSCLC)。
- 对精心选择的97例患者(排除潜在混杂因素)进行详细神经心理测试,评估者设盲。
主要发现
- 167例患者中61例(36.5%)检出脑靶向自身抗体,其中33例(19.8%)为已知抗体,28例(16.8%)为免疫组化检出的未知抗原抗体。
- 97例完成测试者中65例(67.0%)存在认知障碍。
- SCLC患者中,任何自身抗体阳性者认知障碍比值比为11.0(95%CrI 1.2-103.6),独立于年龄、性别和神经功能缺损。
- 针对未知抗原的自身抗体与认知障碍比值比升高相关(OR 2.8;95%CrI 0.6-12.1)。
临床怎么用
- 对肺癌患者,尤其SCLC患者,可考虑评估神经元自身抗体以识别潜在免疫介导的认知障碍。
- 认知障碍的肺癌患者中检测自身抗体可能提示可干预的病因。
局限性
- 单中心研究,样本量有限。
- 神经心理测试仅在97例子组中完成。
- 横断面设计无法确定因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Paraneoplastic neurological syndromes are associated with neuronal autoantibodies, and some of these autoantibodies are associated with neuropsychological symptoms. The most common underlying tumor is lung cancer. The association of neuronal autoantibodies with cognitive deficits has not been systematically investigated in patients with small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). OBJECTIVE: To assess the frequency of neuronal autoantibodies in patients with lung cancer and analyze their association with cognitive function. DESIGN, SETTING, AND PARTICIPANTS: This prospective, cross-sectional study included 167 patients with lung cancer (both SCLC and NSCLC) recruited at a single lung cancer center in Berlin, Germany, between June 2015 and April 2016. Detailed neuropsychological testing was performed in a carefully selected subgroup of 97 patients (from which patients with potential confounding factors were excluded). Investigators were blinded to patients' autoantibody status and cognitive test results. Data were analyzed from May 2016 to December 2019. MAIN OUTCOMES AND MEASURES: Prevalence of neuronal autoantibodies and their association with cognitive impairment. The evaluation of autoantibodies as potential risk factors for cognitive impairment was performed using bayesian logistic regression models. RESULTS: Among 167 patients with lung cancer (median age, 66.0 years [interquartile range, 59.0-72.0 years]; 105 men [62.9%]), 127 had NSCLC, and 40 had SCLC. Brain-directed autoantibodies were detected in 61 of 167 patients (36.5%); 33 patients (19.8%) had known autoantibodies and 28 patients (16.8%) had autoantibodies against currently unknown antigens that were detected through immunohistochemical analysis. Cognitive impairment was found in 65 of 97 patients (67.0%). Among patients with SCLC, the odds of cognitive impairment for those with any autoantibodies was 11-fold higher (odds ratio [OR], 11.0; 95% credible interval [CrI], 1.2-103.6) than that of autoantibody-negative patients, and the increased odds were independent of age, sex, and neurological deficit. Among patients with NSCLC, those with immunoglobin A autoantibodies targeting the N-methyl-d-aspartate receptor had a relevantly increased odds of verbal memory deficits (OR, 182.8; 95% CrI, 3.1-10 852.4). Autoantibodies against currently unknown antigens were also associated with increased odds of cognitive impairment (OR, 2.8; 95% CrI, 0.6-12.1). CONCLUSIONS AND RELEVANCE: In this prospective, cross-sectional study, more than one-third of patients with lung cancer had neuronal autoantibodies that were found to be associated with cognitive impairment. These autoantibodies might represent a potentially treatable mechanism of immune-mediated cognitive impairment among patients with lung cancer.
引用
- Bartels F, Wandrey MM, Aigner A, et al. Association Between Neuronal Autoantibodies and Cognitive Impairment in Patients With Lung Cancer. JAMA Oncol. 2021. PMID: 34196651. doi:10.1001/jamaoncol.2021.2049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。